PE20120668A1 - Un compuesto n,n-dimetil-5-(2-metil-6-((5-metilpirazin-2-il)carbamoil)benzofuran-4-iloxi)pirimidin-carboxamida como activador de glucocinasa - Google Patents
Un compuesto n,n-dimetil-5-(2-metil-6-((5-metilpirazin-2-il)carbamoil)benzofuran-4-iloxi)pirimidin-carboxamida como activador de glucocinasaInfo
- Publication number
- PE20120668A1 PE20120668A1 PE2011001580A PE2011001580A PE20120668A1 PE 20120668 A1 PE20120668 A1 PE 20120668A1 PE 2011001580 A PE2011001580 A PE 2011001580A PE 2011001580 A PE2011001580 A PE 2011001580A PE 20120668 A1 PE20120668 A1 PE 20120668A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- iloxi
- methylpyrazin
- carboxamide
- carbamoil
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 title abstract 2
- 239000012190 activator Substances 0.000 title 1
- KKFDJZZADQONDE-UHFFFAOYSA-N (hydridonitrato)hydroxidocarbon(.) Chemical class O[C]=N KKFDJZZADQONDE-UHFFFAOYSA-N 0.000 abstract 1
- HQSRVYUCBOCBLY-XOOFNSLWSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2s,4r)-2-(4-chlorophenyl)-2-[(4-methyl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CSC=4N(C=NN=4)C)(OC3)C=3C=CC(Cl)=CC=3)=CC=2)C=C1 HQSRVYUCBOCBLY-XOOFNSLWSA-N 0.000 abstract 1
- 239000000883 anti-obesity agent Substances 0.000 abstract 1
- 229940125708 antidiabetic agent Drugs 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 229940125710 antiobesity agent Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- TUOSYWCFRFNJBS-BHVANESWSA-N dirlotapide Chemical compound O=C([C@@H](NC(=O)C=1N(C2=CC=C(NC(=O)C=3C(=CC=CC=3)C=3C=CC(=CC=3)C(F)(F)F)C=C2C=1)C)C=1C=CC=CC=1)N(C)CC1=CC=CC=C1 TUOSYWCFRFNJBS-BHVANESWSA-N 0.000 abstract 1
- 229960002551 dirlotapide Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 229950000884 mitratapide Drugs 0.000 abstract 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 abstract 1
- 229960003086 naltrexone Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
REFERIDA A UN COMPUESTO DE FORMULA I, DONDE Y ES N, C; Z ES C, N, CON LA CONDICION DE QUE Z, Y NO SON IGUALES; R1 Y R2 SON CADA UNO METILO, ETILO; R3 ES 5- METILPIRAZIN-2-ILO; 5-METOXIPIRAZIN-2-ILO, 1-METIL-1H-PIRAZOL-3-ILO. SON COMPUESTOS PREFERIDOS: N,N-DIMETIL-5-(2-METIL-6-((5-METILPIRAZIN-2-IL)CARBAMOIL)BENZOFURAN-4-ILOXI)PIRIMIDIN-2-CARBOXAMIDA; 5-(6-((5-METOXIPIRAZIN-2-IL)CARBAMOIL)-2-METILBENZOFURAN-4-ILOXI)-N,N-DIMETILPIRIMIDIN-2-CARBOXAMIDA; ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ADEMAS: A) UN AGENTE ANTIOBESIDAD SELECCIONADO DE DIRLOTAPIDA, MITRATAPIDA, NALTREXONA, ENTRE OTROS Y B) UN AGENTE ANTI-DIABETICO SELECCIONADO DE METFORMINA, DIABINESA, GLIPIZIDA, GLISOLAMIDA, ENTRE OTROS. DICHOS COMPUESTOS SON UTILES PARA TRATAR O RETRASAR LA PROGESION O COMIENZO DE LA DIABETES TIPO 2 Y TRASTORNOS RELACIONADOS CON LA DIABETES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15909909P | 2009-03-11 | 2009-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120668A1 true PE20120668A1 (es) | 2012-06-01 |
Family
ID=42124287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001580A PE20120668A1 (es) | 2009-03-11 | 2010-03-04 | Un compuesto n,n-dimetil-5-(2-metil-6-((5-metilpirazin-2-il)carbamoil)benzofuran-4-iloxi)pirimidin-carboxamida como activador de glucocinasa |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US8455496B2 (es) |
| EP (2) | EP2406253B1 (es) |
| JP (1) | JP5086480B2 (es) |
| KR (1) | KR101295937B1 (es) |
| CN (1) | CN102388038B (es) |
| AP (1) | AP3179A (es) |
| AR (1) | AR075729A1 (es) |
| AU (1) | AU2010222589B2 (es) |
| BR (1) | BRPI1013246B1 (es) |
| CA (1) | CA2754681C (es) |
| CL (1) | CL2011002185A1 (es) |
| CO (1) | CO6430427A2 (es) |
| CR (1) | CR20110467A (es) |
| CU (1) | CU24036B1 (es) |
| DK (1) | DK2406253T3 (es) |
| DO (1) | DOP2011000279A (es) |
| EA (1) | EA018894B1 (es) |
| EC (1) | ECSP11011306A (es) |
| ES (1) | ES2427279T3 (es) |
| GE (1) | GEP20156239B (es) |
| HR (1) | HRP20130661T1 (es) |
| IL (1) | IL214942A (es) |
| MA (1) | MA33119B1 (es) |
| MY (1) | MY151246A (es) |
| NI (1) | NI201100166A (es) |
| NZ (1) | NZ595024A (es) |
| PE (1) | PE20120668A1 (es) |
| PL (1) | PL2406253T3 (es) |
| PT (1) | PT2406253E (es) |
| RS (1) | RS52903B (es) |
| SI (1) | SI2406253T1 (es) |
| TN (1) | TN2011000454A1 (es) |
| TW (1) | TWI383981B (es) |
| UA (1) | UA99882C2 (es) |
| UY (1) | UY32480A (es) |
| WO (1) | WO2010103437A1 (es) |
| ZA (1) | ZA201106632B (es) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5496409B2 (ja) | 2010-03-19 | 2014-05-21 | ファイザー・インク | ２，３ジヒドロ−１ｈ−インデン−１−イル−２，７−ジアザスピロ［３．５］ノナン誘導体およびグレリン受容体のアンタゴニストまたは逆アゴニストとしてのそれらの使用 |
| ES2546465T3 (es) | 2010-10-29 | 2015-09-23 | Pfizer Inc | Inhibidores de N1/N2-lactama acetil-CoA carboxilasa |
| WO2012143813A1 (en) | 2011-04-22 | 2012-10-26 | Pfizer Inc. | Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors |
| CA2841757A1 (en) | 2011-07-15 | 2013-01-24 | Etzer Darout | Gpr 119 modulators |
| AU2012288493B2 (en) | 2011-07-22 | 2015-08-06 | Pfizer Inc. | Quinolinyl glucagon receptor modulators |
| ES2605565T3 (es) | 2011-08-31 | 2017-03-15 | Pfizer Inc | Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina |
| MX351299B (es) | 2011-11-11 | 2017-10-10 | Pfizer | 2-tiopirimidinonas. |
| HK1206735A1 (en) | 2012-04-06 | 2016-01-15 | 辉瑞公司 | Diacylglycerol acyltransferase 2 inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| WO2013164730A1 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2. |
| US9260455B2 (en) | 2012-09-20 | 2016-02-16 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| EP2931731A1 (en) | 2012-12-11 | 2015-10-21 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| JP6162820B2 (ja) | 2012-12-19 | 2017-07-12 | ファイザー・インク | 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| CA2897678A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| JP6348582B2 (ja) | 2013-10-09 | 2018-06-27 | ファイザー・インク | プロスタグランジンｅｐ３受容体の拮抗薬 |
| DK3119757T3 (en) | 2014-03-17 | 2018-06-18 | Pfizer | DIACYLGYLERIC-ACYL TRANSFERASE-2 INHIBITORS TO USE IN THE TREATMENT OF METABOLIC AND RELATED DISEASES |
| CN106458912B (zh) | 2014-04-04 | 2020-10-27 | 辉瑞公司 | 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途 |
| CN106459088A (zh) | 2014-04-10 | 2017-02-22 | 辉瑞公司 | 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺 |
| CN104387348A (zh) * | 2014-10-27 | 2015-03-04 | 湖南华腾制药有限公司 | 一种苯并呋喃衍生物的制备方法 |
| WO2016092413A1 (en) | 2014-12-10 | 2016-06-16 | Pfizer Inc. | Indole and indazole compounds that activate ampk |
| EP3237401B1 (en) | 2014-12-22 | 2019-03-06 | Pfizer Inc | Antagonists of prostaglandin ep3 receptor |
| ES2885437T3 (es) | 2015-03-03 | 2021-12-13 | Saniona As | Formulación de combinación de tesofensina y metoprolol |
| CN107531647A (zh) | 2015-05-05 | 2018-01-02 | 辉瑞大药厂 | 2‑硫代嘧啶酮类 |
| EP3303303A1 (en) | 2015-05-29 | 2018-04-11 | Pfizer Inc | Novel heterocyclic compounds as inhibitors of vanin-1 enzyme |
| PT3766885T (pt) | 2015-06-17 | 2022-08-09 | Pfizer | Compostos tricíclicos e a sua utilização como inibidores de fosfodiesterase |
| WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| CA2995153A1 (en) | 2015-08-13 | 2017-02-16 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds |
| DK3341367T3 (da) | 2015-08-27 | 2021-04-12 | Pfizer | Bicyklisk-fusionerede heteroaryl- eller arylforbindelser som irak4-modulatorer |
| WO2017037567A1 (en) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
| WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
| AU2016325665A1 (en) | 2015-09-24 | 2018-03-08 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides |
| WO2017051303A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
| US9809579B2 (en) | 2015-12-29 | 2017-11-07 | Pfizer Inc. | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
| US10906888B2 (en) | 2016-07-14 | 2021-02-02 | Pfizer Inc. | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
| WO2019133445A1 (en) | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles as inhibitors of vanin-1 |
| AU2019278015B2 (en) * | 2018-05-31 | 2024-10-03 | Hua Medicine (Shanghai) Ltd. | Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof |
| TWI718644B (zh) | 2018-08-31 | 2021-02-11 | 美商輝瑞股份有限公司 | 用於治療ｎａｓｈ／ｎａｆｌｄ和相關疾病之組合 |
| WO2020051309A2 (en) * | 2018-09-06 | 2020-03-12 | Yale University | Treatments against mosquito-borne viruses based on mosquito salivary gland proteins |
| WO2020102575A1 (en) | 2018-11-16 | 2020-05-22 | Inception Ibd, Inc. | Heterocyclic aminothiazoles and uses thereof |
| EP3972596B1 (en) | 2019-05-20 | 2025-07-16 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
| JP7498199B2 (ja) | 2019-06-28 | 2024-06-11 | ファイザー・インク | 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体 |
| TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶２ 抑制劑 |
| HUE068174T2 (hu) | 2020-02-07 | 2024-12-28 | Gasherbrum Bio Inc | Heterociklusos GLP-1 agonisták |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| FI4161927T3 (fi) | 2020-06-09 | 2024-10-03 | Pfizer | Spiroyhdisteitä melanokortiini-4-reseptorin antagonisteina ja niiden käyttöjä |
| US20250066337A1 (en) | 2021-08-26 | 2025-02-27 | Pfizer Inc. | Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide |
| KR20240110881A (ko) | 2021-12-01 | 2024-07-16 | 화이자 인코포레이티드 | 당뇨병, 신장 질환, nash 및 심부전의 치료를 위한 분지쇄 알파 케토산 데하이드로게나제 키나제 억제제로서 3-페닐-1-벤조티오펜-2-카복실산 유도체 |
| ES3039638T3 (en) | 2021-12-06 | 2025-10-23 | Pfizer | Melanocortin 4 receptor antagonists and uses thereof |
| WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
| EP4508047A1 (en) | 2022-04-14 | 2025-02-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| IL319486A (en) | 2022-10-07 | 2025-05-01 | Pfizer | HSD17B13 Inhibitors and/or Retarders |
| IL319392A (en) | 2022-10-18 | 2025-05-01 | Pfizer | Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations |
| WO2024118524A1 (en) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Azaindole compounds and their use as phosphodiesterase inhibitors |
| AU2023396387A1 (en) | 2022-12-15 | 2025-06-26 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
| AU2023393326A1 (en) | 2022-12-16 | 2025-06-19 | Pfizer Inc. | 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof |
| WO2024214038A1 (en) | 2023-04-14 | 2024-10-17 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2025099566A1 (en) | 2023-11-08 | 2025-05-15 | Pfizer Inc. | A crystalline form of 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid |
| WO2025163561A1 (en) | 2024-02-01 | 2025-08-07 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2025224599A1 (en) | 2024-04-22 | 2025-10-30 | Pfizer Inc. | Pyrrolidine-based glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5795984A (en) * | 1980-12-05 | 1982-06-15 | Tanabe Seiyaku Co Ltd | Pyridinecarboxamide derivative and its preparation |
| US5399564A (en) | 1991-09-03 | 1995-03-21 | Dowelanco | N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides |
| RU2105005C1 (ru) | 1992-07-03 | 1998-02-20 | Кумиай Кемикал Индастри Ко., Лтд. | Конденсированное гетероциклическое производное, способ его получения и гербицидное средство |
| WO1996003399A1 (de) * | 1994-07-22 | 1996-02-08 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Dihydrobenzofurane |
| DE4434637A1 (de) | 1994-09-28 | 1996-04-04 | Hoechst Schering Agrevo Gmbh | Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
| CN1160399A (zh) * | 1994-10-13 | 1997-09-24 | 美国辉瑞有限公司 | 苯并吡喃和苯并稠合化合物、其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途 |
| NZ285154A (en) * | 1994-10-13 | 1998-11-25 | Pfizer | Optionally heterocyclically substituted benzopyran and benzo-fused derivatives, preparation and use as leukotriene antagonists |
| DE19603576A1 (de) | 1996-02-01 | 1997-08-07 | Bayer Ag | Acylierte 4-Amino und 4-Hydrazinopyrimidine |
| US5972936A (en) * | 1996-05-20 | 1999-10-26 | Darwin Discover Limited | Benzofuran carboxamides and their therapeutic use |
| EP0923568B9 (en) * | 1996-08-19 | 2003-08-13 | ALTANA Pharma AG | Novel benzofuran-4-carboxamides |
| WO1999040085A1 (en) * | 1998-02-09 | 1999-08-12 | Darwin Discovery Limited | Benzofuran-4-carboxamides and their therapeutic use |
| DE60036918D1 (de) * | 1999-01-22 | 2007-12-13 | Elan Pharm Inc | Verbindungen die die vla-4 vermittelte adhäsion von leukozyten inhibieren |
| SE9901573D0 (sv) | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| AU2001288623A1 (en) | 2000-09-05 | 2002-03-22 | Tularik, Inc. | Fxr modulators |
| EP1343763A1 (en) | 2000-11-20 | 2003-09-17 | Bristol-Myers Squibb Company | Pyrodone derivatives as ap2 inhibitors |
| EP1341774B1 (en) | 2000-12-06 | 2006-02-01 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
| EP1354882A1 (en) | 2000-12-27 | 2003-10-22 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
| JP4104983B2 (ja) | 2001-02-28 | 2008-06-18 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体 |
| EP1403255A4 (en) * | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | RHO KINASE INHIBITORS |
| SE0102300D0 (sv) * | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| WO2003035621A1 (en) | 2001-10-22 | 2003-05-01 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them |
| PT1490064E (pt) | 2002-02-14 | 2009-12-28 | Pharmacia Corp | Piridinonas substituídas como moduladores de p38 map-quinase |
| CN100357283C (zh) * | 2002-04-02 | 2007-12-26 | 中国科学院上海药物研究所 | 一类甲硫氨酰氨肽酶抑制剂 |
| MXPA04010780A (es) | 2002-05-03 | 2005-03-07 | Warner Lambert Co | Antagonistas de bombesina. |
| US7754738B2 (en) | 2002-06-13 | 2010-07-13 | E.I. Du Pont De Nemours And Company | Pyrazole and pyrrole carboxamide insecticides |
| JP4302967B2 (ja) * | 2002-11-18 | 2009-07-29 | パイオニア株式会社 | 楽曲検索方法、楽曲検索装置及び楽曲検索プログラム |
| GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| EP1433778A1 (en) | 2002-12-23 | 2004-06-30 | Jerini AG | Use of nitriles as rotamase inhibitors |
| WO2004072066A1 (en) | 2003-02-11 | 2004-08-26 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| CN100378094C (zh) * | 2003-02-13 | 2008-04-02 | 万有制药株式会社 | 2-吡啶甲酰胺衍生物 |
| PE20050194A1 (es) * | 2003-02-13 | 2005-04-23 | Banyu Pharma Co Ltd | Derivados de piridina-2-carboxamida como activadores de glucoquinasa |
| CL2004000306A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
| AU2004215514B2 (en) * | 2003-02-26 | 2010-03-04 | Msd K.K. | Heteroarylcarbamoylbenzene derivative |
| BRPI0412694A (pt) * | 2003-07-15 | 2006-10-03 | Smithkline Beecham Corp | compostos |
| WO2005011670A1 (en) * | 2003-08-01 | 2005-02-10 | Chugai Seiyaku Kabushiki Kaisha | Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors |
| CL2004002050A1 (es) | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| SE0303480D0 (sv) * | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
| JP4700684B2 (ja) | 2004-04-02 | 2011-06-15 | ノバルティス アーゲー | ２型糖尿病の処置に有用なグルコキナーゼアクティベーターとしてのスルホンアミド−チアゾロピリジン誘導体 |
| GEP20094723B (en) | 2004-05-25 | 2009-07-10 | Pfizer Prod Inc | Tetraazabenzo [e] azulene derivatives and analogs thereof |
| US7879839B2 (en) | 2004-07-29 | 2011-02-01 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| CA2578349A1 (en) | 2004-09-01 | 2006-03-16 | Rigel Pharmaceuticals, Inc. | Synthesis of 2,4-pyrimidinediamine compounds |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| SE0403006D0 (sv) * | 2004-12-09 | 2004-12-09 | Biovitrum Ab | New compounds |
| KR20070088798A (ko) * | 2004-12-21 | 2007-08-29 | 에프. 호프만-라 로슈 아게 | 크로만 유도체 및 그의 5-ｈｔ 수용체 리간드로서의 용도 |
| JP4167218B2 (ja) | 2004-12-22 | 2008-10-15 | 株式会社メタル建材 | 薄板用タッピンねじ |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| TW200700392A (en) | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
| JP2008534664A (ja) | 2005-04-06 | 2008-08-28 | アストラゼネカ アクチボラグ | 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用 |
| US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| EP1921074A1 (en) | 2005-08-31 | 2008-05-14 | Astellas Pharma Inc. | Thiazole derivative |
| JP2009013065A (ja) * | 2005-10-14 | 2009-01-22 | Astellas Pharma Inc | 縮合へテロ環化合物 |
| EP1951680A4 (en) | 2005-11-15 | 2011-08-10 | Astrazeneca Ab | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE |
| WO2007104034A2 (en) * | 2006-03-08 | 2007-09-13 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2007117995A2 (en) | 2006-03-30 | 2007-10-18 | Takeda San Diego, Inc. | Kinase inhibitors |
| CA2648852C (en) * | 2006-04-20 | 2012-12-11 | Pfizer Products Inc. | Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
| US7842713B2 (en) * | 2006-04-20 | 2010-11-30 | Pfizer Inc | Fused phenyl amido heterocyclic compounds |
| WO2008079787A2 (en) | 2006-12-20 | 2008-07-03 | Takeda San Diego, Inc. | Glucokinase activators |
| JP2010138073A (ja) | 2007-03-30 | 2010-06-24 | Taisho Pharmaceutical Co Ltd | ピコリン酸アミド化合物 |
| CN101679365A (zh) | 2007-06-08 | 2010-03-24 | 艾德维纳斯医疗私人有限公司 | 作为葡萄糖激酶激活剂的新型吡咯-2-甲酰胺衍生物、它们的制造方法和药学应用 |
| EP2389374A1 (en) * | 2009-01-20 | 2011-11-30 | Pfizer Inc. | Substituted pyrazinone amides |
-
2010
- 2010-03-04 CA CA2754681A patent/CA2754681C/en not_active Expired - Fee Related
- 2010-03-04 AU AU2010222589A patent/AU2010222589B2/en not_active Ceased
- 2010-03-04 EP EP10708644.9A patent/EP2406253B1/en active Active
- 2010-03-04 NZ NZ595024A patent/NZ595024A/xx not_active IP Right Cessation
- 2010-03-04 RS RS20130355A patent/RS52903B/sr unknown
- 2010-03-04 EP EP13158856.8A patent/EP2604604A1/en not_active Withdrawn
- 2010-03-04 PL PL10708644T patent/PL2406253T3/pl unknown
- 2010-03-04 HR HRP20130661AT patent/HRP20130661T1/hr unknown
- 2010-03-04 KR KR1020117023630A patent/KR101295937B1/ko not_active Expired - Fee Related
- 2010-03-04 UA UAA201110834A patent/UA99882C2/uk unknown
- 2010-03-04 GE GEAP201313280A patent/GEP20156239B/en unknown
- 2010-03-04 WO PCT/IB2010/050943 patent/WO2010103437A1/en not_active Ceased
- 2010-03-04 SI SI201030278T patent/SI2406253T1/sl unknown
- 2010-03-04 MY MYPI2011004231 patent/MY151246A/en unknown
- 2010-03-04 BR BRPI1013246-5A patent/BRPI1013246B1/pt not_active IP Right Cessation
- 2010-03-04 ES ES10708644T patent/ES2427279T3/es active Active
- 2010-03-04 PE PE2011001580A patent/PE20120668A1/es not_active Application Discontinuation
- 2010-03-04 MA MA34164A patent/MA33119B1/fr unknown
- 2010-03-04 EA EA201190158A patent/EA018894B1/ru not_active IP Right Cessation
- 2010-03-04 PT PT107086449T patent/PT2406253E/pt unknown
- 2010-03-04 DK DK10708644.9T patent/DK2406253T3/da active
- 2010-03-04 CN CN201080016137.6A patent/CN102388038B/zh active Active
- 2010-03-04 AP AP2011005882A patent/AP3179A/xx active
- 2010-03-04 JP JP2011553571A patent/JP5086480B2/ja not_active Expired - Fee Related
- 2010-03-09 UY UY0001032480A patent/UY32480A/es not_active Application Discontinuation
- 2010-03-10 US US12/720,724 patent/US8455496B2/en active Active
- 2010-03-10 TW TW099106974A patent/TWI383981B/zh active
- 2010-03-10 AR ARP100100715A patent/AR075729A1/es unknown
-
2011
- 2011-08-31 CR CR20110467A patent/CR20110467A/es unknown
- 2011-09-01 IL IL214942A patent/IL214942A/en active IP Right Grant
- 2011-09-02 CU CU2011000168A patent/CU24036B1/es active IP Right Grant
- 2011-09-02 NI NI201100166A patent/NI201100166A/es unknown
- 2011-09-05 CL CL2011002185A patent/CL2011002185A1/es unknown
- 2011-09-06 EC EC2011011306A patent/ECSP11011306A/es unknown
- 2011-09-08 TN TN2011000454A patent/TN2011000454A1/fr unknown
- 2011-09-08 DO DO2011000279A patent/DOP2011000279A/es unknown
- 2011-09-09 ZA ZA2011/06632A patent/ZA201106632B/en unknown
- 2011-09-12 CO CO11117871A patent/CO6430427A2/es active IP Right Grant
-
2013
- 2013-05-22 US US13/899,851 patent/US8735396B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120668A1 (es) | Un compuesto n,n-dimetil-5-(2-metil-6-((5-metilpirazin-2-il)carbamoil)benzofuran-4-iloxi)pirimidin-carboxamida como activador de glucocinasa | |
| AR060150A1 (es) | Heteropentaciclos activos como inhibidores de quinasas, y su uso para tratar trastornos de la proliferacion celular | |
| ATE482210T1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
| AR060536A1 (es) | Agonista del receptor de glucocorticoides y composiciones farmaceuticas | |
| NO20070487L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
| CL2009000394A1 (es) | Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
| ECSP077299A (es) | Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos | |
| JOP20210005A1 (ar) | عوامل تحلل مستقبلات الإستروجين الانتقائية | |
| NO20082285L (no) | 3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer | |
| CL2008000212A1 (es) | Compuestos derivados de fenotiazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes, reducir los niveles de glucemia, adiccion a nicotina, adiccion al alcohol, trastornos del sistema nervioso central, entre | |
| EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
| CL2011001082A1 (es) | Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2. | |
| PE20080697A1 (es) | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion | |
| UA83311C2 (en) | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | |
| CL2008001839A1 (es) | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. | |
| NO20064365L (no) | Terapeutisk forbindelse | |
| BR112012016797A2 (pt) | intensificador dinâmico de baixo utilizando compressor com equalizador incorporado | |
| EA200801738A1 (ru) | Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа | |
| CL2007002890A1 (es) | Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad. | |
| CL2008002247A1 (es) | Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros. | |
| BRPI0714885B8 (pt) | compostos terapêuticos e seu uso | |
| NO20092092L (no) | Arylsulfamidderivater og fremgangsmater for anvendelse derav | |
| NO20065678L (no) | 3-(4-heteroarylcykloheksylamino) cyklopentankarboksamider som modulatorer for kjemokinreseptorer. | |
| NO20070789L (no) | Nikotinreseptoragonister for behandling av betennelsessykdommer | |
| EA201071369A1 (ru) | Композиции для лечения выпадения волос |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |